VRCA Stock Risk & Deep Value Analysis
Verrica Pharmaceuticals Inc
DVR Score
out of 10
The Bottom Line on VRCA
We analyzed Verrica Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VRCA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
VRCA Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
VRCA Deep Value Analysis
VRCA Red Flags & Warning Signs
- âš
Continued slower-than-expected YCANTH commercial adoption and revenue growth
- âš
Announcement of highly dilutive equity financing
- âš
Unexpected competition (e.g., new off-label treatment gain traction, though regulatory moat is strong)
- âš
Negative results from cash runway updates in earnings calls
Unlock VRCA Red Flags & Risk Warnings
Create a free account to see the full analysis
VRCA Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The FDA approval for YCANTH (cantharidin for Molluscum Contagiosum) grants significant market exclusivity and intellectual property protection, creating a durable barrier to entry for direct competitors. Any new treatment would need to undergo extensive and costly clinical trials and regulatory review, making the moat resilient for the next 10-20 years.
VRCA Competitive Moat Analysis
Sign up to see competitive advantages
VRCA Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early-May 2026), focusing on YCANTH sales growth and cash burn
- •Q2 2026 Earnings (Estimated early-Aug 2026), demonstrating revenue acceleration and improved gross-to-net
- •Updates on payer coverage and reimbursement for YCANTH
Medium-Term (6-18 months)
- •Announcement of strategic partnerships for ex-U.S. commercialization of YCANTH
- •Successful and non-dilutive (or minimally dilutive) capital raise
- •Initial clinical data for potential YCANTH label expansion or pipeline assets
Long-Term (18+ months)
- •YCANTH achieving peak sales estimates and becoming standard-of-care for Molluscum
- •Diversification of product portfolio beyond YCANTH
- •Market leadership in pediatric dermatology
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
VRCA Bull Case: What Could Go Right
- ✓
Consistent quarter-over-quarter acceleration in YCANTH net product sales
- ✓
Improvement in gross-to-net percentages for YCANTH
- ✓
Successful and non-dilutive capital raise or clear path to cash flow positivity
- ✓
Reduction in quarterly cash burn
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
